Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 12/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4881662 | 0.89 | TDP1 (0.47) | GAAALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL4877112 | 0.88 | GAA (0.48) | GAAALDH1A1MAPTPOLBHSD17B10 | |
| SCHEMBL5239859 | 0.87 | GAA (0.40) | GAAALDH1A1MAPTPOLBHSD17B10 | |
| SCHEMBL14066581 | 0.83 | MAPT (0.59) | GAAALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL5240553 | 0.83 | GAA (0.40) | GAAALDH1A1MAPTPOLBHSD17B10 | |
| SCHEMBL14066580 | 0.78 | MAPT (0.53) | GAAALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL17142697 | 0.72 | NPC1 (0.51) | GAAALDH1A1MAPTPOLBHSD17B10 | |
| SCHEMBL17148072 | 0.71 | GRM4 (0.48) | GAAALDH1A1MAPTPOLBHSD17B10 | |
| SCHEMBL2599179 | 0.70 | MAPT (0.44) | ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL71052 | 0.69 | ALDH1A1 (0.47) | GAAALDH1A1MAPTPOLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | F2, UQCRB, F12 | GAA 3652/4885ALDH1A1 348/4885MAPT 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.